Table 1: Comparison of the distribution of clinical and pathologic characteristics of the 260 women in the cohort study stratified by MRI staging.

Clinical characteristicsMRI
T0
(n=57)
MRI
T1b
(n=139)
MRI
T2a
(n=10)
MRI
T2b
(n=54)
P-value

Age(y)47.649.547.952.10.207

Parity2.12.21.92.30.773

Operative procedure0.01

 Open modified radical hysterectomy2(3.5)1(0.7)0(0)0(0)

 Open radical hysterectomy9(15.8)47(33.8)2(20.0)25(46.3)

 Laparoscopic modified radical hysterectomy20(35.1)9(6.5)0(0)1(1.9)

 Laparoscopic radical hysterectomy22(38.6)77(55.4)8(80.0)28(51.9)

 Laparoscopic radical trachelectomy3(5.3)3(2.20(0)0(0)

 Robotic radical hysterectomy1(1.8)1(0.7)0(0)0(0)

 Robotic trachelectomy0(0)1(0.7)0(0)0(0)

Menopause 0.004

 No37(64.9)79(56.8)5(50)21(38.9)

 Yes20(35.1))60(43.2)5(50)33(61.1)

Cesarean section0.101

 No54(94.7)122(87.8)7(70)46(85.2)

 Yes3(5.3)17(12.2)3(30)8(14.8)

History of at least one normal delivery 0.381

 No7(12.3)18(12.9)5(50)8(14.8)

 Yes50(87.7)121(87.1)5(50)46(85.2)

BMI 24.123.924.323.80.948

SCC Ag (ng/ml) 0.92.73.910.1<0.0001

CEA(U/ml) 2.74.911.112.30.098

CA 125(U/ml) 18.81521.422.80.441

Histology0.166

 Squamous35(61.4)94(67.6)8(80.0)41(75.9)

 Adenocarcinoma21(36.8)38(27.3)2(20.0)11(20.4)

 Adeno-squamous1(1.8)7(5)0(0.0)2(3.7)

Grade0.132

 124(42.1)20(14.4)0(0.0)8(14.8)

 219(33.3)77(55.4)5(50.0)29(53.7)

 35(8.8)32(23.0)4(40.0)13(24.1)

 Unknown9(15.8)10(7.2)1(10.0)4(7.4)

Biopsy type<0.0001

 Punch biopsy21(36.8)106(76.3)8(80.0)41(77.4)

 LEEP36(63.2)33(23.7)2(20.0)12(22.6)

Clinical FIGO tumor stage<0.0001

 IA15(26.3)0(0.0)0(0.0)0(0.0)

 IB142(73.7)102(73.4)4(40.0)20(37.0)

 IB20(0.0)23(16.5)3(30.0)26(48.1)

 IIA10(0.0)6(4.3)2(20.0)4(7.4)

 IIA20(0.0)8(5.8)1(10.0)4(7.4)

RH T category (final pathologic_stage )<0.0001

 T1a15(26.3)0(0.0)0(0.0)0(0.0)

 T0b116(28.1)3(2.2)0(0.0)0(0.0)

 T1b126(45.6)96(66.9)6(60.0)11(20.4)

 T1b20(0.0)25(18.0)1(10.0)11(20.4)

 T2a10(0.0)1(0.7)0(0.0)3(5.6)

 T2a20(0.0)1(0.7)1(10.0)0(0.0)

 T2b0(0.0)16(11.5)2(20.0)29(53.7)

Pathologic Tumor size 0.6012.934.244.68<0.0001

Pathologic tumor size <0.0001

 0-≤143(75.4)19(13.7)0(0.0)0(0.0)

 1-≤210(17.5)21(15.1)0(0.0)2(3.7)

 2-≤32(3.5)46(33.1)2(20.0)9(16.7)

 3-≤42(3.5)21(15.1)4(40.0)11(20.4)

 4-≤50(0.0)18(12.9)3(30.0)14(25.9)

 5-≤60(0.0)13(9.4)0(0.0)7(13.0)

 6-≤70(0.0)1(0.7)0(0.0)7(13.0)

 >70(0.0)0(0.0)1(10.0)4(7.4)

LVSI<0.0001

 Yes4(7.0)53(38.1)7(70.0)36(66.7)

 No53(93.0)86(61.9)3(30.0)18(33.3)

Pathologic deep stromal invasion<0.0001

 Inner 1/348(84.2)27(19.4)2(20.0)0(0.0)

 Middle 1/36(10.5)44(31.7)3(30.0)2(3.7)

 Outer 1/33(5.3)68(48.9)5(50.0)52(96.3)

Pathologic parametrial invasion<0.0001

 No57(100.0)124(89.2)8(80.0)25(46.3)

 Yes0(0.0)15(10.8)2(20.0)29(53.7)

Pathologic parametrial invasion laterality<0.0001

 Negative57(100.0)124(89.2)8(80.0)22(40.7)

 Unilateral0(0.0)8(5.8)1(10.0)14(25.9)

 Bilateral0(0.0)7(5.0)1(10.0)18(33.3)

Pathologic pelvic LN involvement<0.0001

 Negative55(96.5)115(82.7)6(60.0)30(55.6)

 Positive2(3.5)24(17.3)4(40.0)24(44.4)

Pathologic para-aortic LN involvement0.001

 Negative51(89.5)120(86.3)9(90.0)45(83.3)

 Positive0(0.0)10(7.2)1(10.0)8(14.8)

 Not done6(10.5)9(6.5)0(0.0)1(1.9)

Pathological uterine involvement

 No56(98.2)125(89.9)8(80.0)26(48.1)

 Yes1(1.8)14(10.1)2(20.0)28(51.9)

MRI tumor size0.002.894.064.61<0.0001

MRI pelvic LN involvement

 Negative57(100.0)128(92.1)7(70.0)36(66.7)

 Positive0(0.0)11(7.9)3(30.0)18(33.3)

MRI para-aortic LN involvement0.46

 Negative57(100.0)137(98.6)10(100.0)53(98.1)

 Positive0(0.0)2(1.4)0(0.0)1(1.9)

MRI uterine corpus invasion

 No57(100.0)127(91.4)8(80.0)27(50.0)

 Yes0(0.0)12(8.6)2(20.0)27(50.0)

MRI deep stromal invasion

 No invasion57(100.0)2(1.4)0(0.0)0(0.0)

 Partial invasion0(0.0)79(56.8)6(60.0)3(5.6)

 Complete invasion0(0.0)58(41.7)4(40.0)51(94.4)

The data are presented as the number (%) or the mean ± SD.
FIGO, International Federation of Gynecology and Obstetrics; RH, radical hysterectomy; LVSI, lymphovascular stromal invasion; LN, lymph node; CA 125, carbohydrate antigen 125; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; MRI, magnetic resonance imaging.